Acrivon Therapeutics Shareholders’ Equity Growth & History (ACRV)
Acrivon Therapeutics's shareholders’ equity was $112.5M for fiscal 2025.
View full Acrivon Therapeutics company overviewAcrivon Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $112.5M | −$64.3M | −36.35% |
| 2024 | 2024-12-31 | $176.8M | $55.6M | +45.87% |
| 2023 | 2023-12-31 | $121.2M | −$49.3M | −28.91% |
| 2022 | 2022-12-31 | $170.5M | $194.3M | — |
| 2021 | 2021-12-31 | −$23.8M | — | — |
Acrivon Therapeutics quarterly shareholders’ equity
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $86.7M | −$56.4M | −39.41% |
| Q1 2026 | 2026-03-31 | $95.5M | −$64.9M | −40.45% |
| Q4 2025 | 2025-12-31 | $112.5M | −$64.3M | −36.35% |
| Q3 2025 | 2025-09-30 | $128.6M | −$68.3M | −34.68% |
| Q2 2025 | 2025-06-30 | $143.0M | −$73.0M | −33.80% |
| Q1 2025 | 2025-03-31 | $160.4M | $52.4M | +48.54% |
| Q4 2024 | 2024-12-31 | $176.8M | $55.6M | +45.87% |
| Q3 2024 | 2024-09-30 | $196.9M | $58.7M | +42.52% |
| Q2 2024 | 2024-06-30 | $216.1M | $66.9M | +44.83% |
| Q1 2024 | 2024-03-31 | $108.0M | −$52.5M | −32.71% |
| Q4 2023 | 2023-12-31 | $121.2M | −$49.3M | −28.91% |
| Q3 2023 | 2023-09-30 | $138.1M | $183.8M | — |
| Q2 2023 | 2023-06-30 | $149.2M | — | — |
| Q1 2023 | 2023-03-31 | $160.5M | — | — |
| Q4 2022 | 2022-12-31 | $170.5M | $194.3M | — |
| Q3 2022 | 2022-09-30 | −$45.6M | — | — |
| Q4 2021 | 2021-12-31 | −$23.8M | — | — |
Acrivon Therapeutics shareholders’ equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Acrivon Therapeutics's shareholders’ equity increased from −$23.8M to $112.5M, a change of $136.3M. The latest reported quarter, Q2 2026, shows $86.7M.
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acrivon Therapeutics source filings ↗